Needham sees over 130% upside in this Biotech stock
Tweet Send to a Friend
Needham & Company analyst Ami Fadia expanded research coverage of biotech companies with a small-cap company.The analyst recently initiated research ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


